Enumera Molecular - About the company
Enumera Molecular is a series B company based in Ann Arbor (United States), founded in 2022. It operates as a Developer of liquid biopsy tools. Enumera Molecular has raised $31M in funding from Arboretum Ventures. The company has 537 active competitors, including 158 funded and 102 that have exited. Its top competitors include companies like Guardant Health, Natera and BillionToOne.
Company Details
Developer of liquid biopsy tools. The company manufactures tools for developing rapid, low-cost solutions for the assessment of biomolecules via liquid biopsy.
Key Metrics
Founded Year
2022
Location
Ann Arbor, United States
Stage
Series B
Total Funding
$31M in 2 rounds
Latest Funding Round
Investors
Ranked
192nd among 537 active competitors
Employee Count
17 as on Sep 30, 2026
Similar Companies
Sign up to download Enumera Molecular's company profile
Enumera Molecular's funding and investors
Enumera Molecular has raised a total funding of $31M over 2 rounds. Its first funding round was on May 05, 2022. Enumera Molecular has 1 institutional investor.
Here is the list of recent funding rounds of Enumera Molecular:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jul 16, 2026 | 5734048 | Series B | 7278099 | 6949550 | 8126385 | 5456620 |
May 05, 2022 | 8910732 | Series A | 3884683 | 8600598 | 4111641 |
Access funding benchmarks and valuations. Sign up today!View details of Enumera Molecular's funding rounds and investors
Enumera Molecular's founders and board of directors
Founder? Claim ProfileEnumera Molecular's employee count trend
Enumera Molecular has 17 employees as of Sep 26. Here is Enumera Molecular's employee count trend over the years:
Uncover Enumera Molecular's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Enumera Molecular's Competitors and alternates
Top competitors of Enumera Molecular include Guardant Health, Natera and BillionToOne. Here is the list of Top 10 competitors of Enumera Molecular, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Guardant Health 2012, Redwood City (United States), Public | Developer of digital sequencing technology for cancer detection | $557M | 80/100 | |
2nd | Natera 2004, Redwood City (United States), Public | Developer of cell-free DNA testing for oncology, women’s health, and organ health | $152M | 79/100 | |
3rd | BillionToOne 2015, San Francisco (United States), Public | Provider of cell-free cancer liquid biopsy test | $389M | 71/100 | |
4th | Caris Life Sciences 1996, Irving (United States), Public | Developer of panomic disease profiling technologies for cancer precision medicine | $1.23B | 67/100 | |
5th | Foundation Medicine 2010, Cambridge (United States), Acquired | Provider of genomics-based diagnostics test for cancer | $96.5M | 66/100 | |
6th | Freenome Health 2014, United States, Series E | Provider of a deep learning platform for detecting circulating cancer-related markers | $1.35B | 66/100 | |
7th | Myriad Genetics 1991, United States, Public | Developer of molecular diagnostics and personalized medicine for cancer | - | 66/100 | |
8th | Online platform for genetic and diagnostic health testing that helps identify health risks | $67.6M | 65/100 | ||
9th | NeoGenomics 2002, Fort Myers (United States), Public | Provider of cancer genetic diagnostic services | - | 65/100 | |
10th | Saga Diagnostics 2016, Morrisville (United States), Acquired | Provider of tests for detection and analysis of circulating tumor DNA | $17.9M | 65/100 | |
192nd |  Enumera Molecular 2022, Ann Arbor (United States), Series B | Developer of liquid biopsy tools | $31M | 33/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Enumera Molecular's competitors? Click here to see the top ones
Enumera Molecular's Investments and acquisitions
Enumera Molecular has made no investments or acquisitions yet.
Reports related to Enumera Molecular
Here is the latest report on Enumera Molecular's sector:
News related to Enumera Molecular
•
Biora Therapeutics announces new capital investmentSeeking Alpha•Mar 11, 2024•Biora Therapeutics, Context Capital Management, Enumera Molecular
•
Enumera Molecular Acquires Progenity Liquid Biopsy Tech, Raises $12.5M in Series A RoundGenomeWeb•May 05, 2022•Enumera Molecular
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Enumera Molecular
Explore our recently published companies
- Laboratoires PanPharma - Fougeres based, 2014 founded, Funding Raised company
- Armas Pharmaceuticals - Manalapan Township based, 2018 founded, Unfunded company
- iQone Healthcare Group - Versoix based, 1979 founded, Acquired company
- Relic Biotechnology - Pune based, 2010 founded, Unfunded company
- Onepick - Unfunded company
- Geologiclabs - 2023 founded, Unfunded company
